Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Burning Rock Biotech Ltd (BNR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: BNR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.03
1 Year Target Price $4.03
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.99% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.95M USD | Price to earnings Ratio - | 1Y Target Price 4.03 |
Price to earnings Ratio - | 1Y Target Price 4.03 | ||
Volume (30-day avg) 1 | Beta 0.74 | 52 Weeks Range 2.18 - 7.90 | Updated Date 06/30/2025 |
52 Weeks Range 2.18 - 7.90 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-03 | When - | Estimate - | Actual -0.1724 |
Profitability
Profit Margin -45.59% | Operating Margin (TTM) -11.41% |
Management Effectiveness
Return on Assets (TTM) -14.39% | Return on Equity (TTM) -37.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -30115407 | Price to Sales(TTM) 0.06 |
Enterprise Value -30115407 | Price to Sales(TTM) 0.06 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 9034110 | Shares Floating 48307975 |
Shares Outstanding 9034110 | Shares Floating 48307975 | ||
Percent Insiders 3.92 | Percent Institutions 59.86 |
Analyst Ratings
Rating 1 | Target Price 4.03 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Burning Rock Biotech Ltd
Company Overview
History and Background
Burning Rock Biotech Ltd. was founded in 2014, specializing in cancer therapy selection and early detection through NGS-based testing. They focus on the Chinese market, evolving from clinical testing services to a platform encompassing central lab and in-hospital solutions.
Core Business Areas
- Therapy Selection: Provides NGS-based testing services to guide personalized cancer therapy decisions. Includes test reports and consultations for oncologists.
- Early Detection: Develops and commercializes NGS-based assays for the early detection of various cancers in asymptomatic individuals.
Leadership and Structure
The leadership team consists of key executives focused on R&D, operations, and commercialization. The organizational structure likely involves distinct departments for research, development, marketing, and sales, conforming to best practices for biotech.
Top Products and Market Share
Key Offerings
- BR-Lung Panel: NGS-based assay for lung cancer therapy selection. Market share data is difficult to obtain, but it is a leading product in China. Competitors include AmoyDx and Geneplus.
- OncoScreen Plus: An early cancer detection test using NGS. Market share is evolving as the early detection market matures in China. Competitors include Grail (Illumina) and Singlera Genomics.
Market Dynamics
Industry Overview
The NGS-based cancer diagnostics market is growing rapidly, driven by advancements in genomics and precision medicine. China represents a significant portion of global growth, with increasing adoption of personalized cancer therapies and early detection programs.
Positioning
Burning Rock Biotech Ltd. is positioned as a key player in the Chinese NGS-based cancer diagnostics market. Their competitive advantages include a strong brand reputation, comprehensive product portfolio, and established relationships with hospitals and physicians.
Total Addressable Market (TAM)
The estimated TAM for NGS-based cancer diagnostics in China is several billion USD and is growing. Burning Rock Biotech is positioned to capitalize on a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in China
- Comprehensive product portfolio covering therapy selection and early detection
- Established relationships with hospitals and physicians
- Advanced NGS technology platform
Weaknesses
- Concentration in the Chinese market
- High R&D expenses
- Regulatory risks
- Profitability challenges
Opportunities
- Expansion into new cancer types
- Development of companion diagnostics
- International expansion
- Partnerships with pharmaceutical companies
Threats
- Competition from domestic and international players
- Price pressures
- Changes in reimbursement policies
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- AmoyDx (No US Symbol)
- Geneplus (No US Symbol)
- Illumina (ILMN)
Competitive Landscape
Burning Rock Biotech has a strong position in the Chinese market, but faces competition from domestic and international players. Illumina is a global leader in NGS technology, while AmoyDx is a major player in molecular diagnostics in China.
Growth Trajectory and Initiatives
Historical Growth: Burning Rock has demonstrated growth, influenced by market dynamics and product adoption within China
Future Projections: Future growth projections are unavailable. Analyst estimates would be needed.
Recent Initiatives: Recent initiatives often include product launches, partnerships, and regulatory approvals.
Summary
Burning Rock Biotech is a key player in the Chinese NGS-based cancer diagnostics market, offering therapy selection and early detection services. Its strength lies in its brand recognition and comprehensive product portfolio within China. However, the company faces risks from competition, regulatory changes, and profitability pressures. Its future depends on strategic initiatives such as expanding product lines and reaching new markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Burning Rock Biotech Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-06-12 | Founder, Chairman & CEO Mr. Yusheng Han | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 674 | Website https://www.brbiotech.com |
Full time employees 674 | Website https://www.brbiotech.com | ||
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS) based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various cancer types, including pan-cancer, lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, and ovarian cancer. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples, and OncoCompass, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore, which assesses microsatellite loci related to MSI status and detects mutations in genes associated with gastrointestinal cancers. It also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of the key products. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.